scispace - formally typeset
C

Chang Yu

Researcher at Vanderbilt University Medical Center

Publications -  128
Citations -  4071

Chang Yu is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Population & Internal medicine. The author has an hindex of 33, co-authored 118 publications receiving 3339 citations. Previous affiliations of Chang Yu include Vanderbilt University & Yale University.

Papers
More filters
Journal ArticleDOI

Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial ☆

Loren Laine, +4 more
- 01 Aug 2004 - 
TL;DR: Addition of a cyclooxygenase-2 (COX-2) selective inhibitor to low-dose aspirin increased ulcer incidence, to a rate not significantly less than a nonselective nonsteroidal anti-inflammatory drug (NSAID) alone.
Journal ArticleDOI

A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension.

Anna R. Hemnes, +21 more
- 01 Jun 2018 - 
TL;DR: Augmentation of ACE2 in a pilot study was well tolerated, associated with improved pulmonary haemodynamics and reduced markers of oxidant and inflammatory mediators and Targeting this pathway may be beneficial in human PAH.
Journal ArticleDOI

Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease

Jorge L. Gamboa, +9 more
- 01 May 2016 - 
TL;DR: Mitochondrial abnormalities, which are common in skeletal muscle from patients with CKD stage 5, may explain the muscle dysfunction associated with frailty and sarcopenia in CKD.
Journal ArticleDOI

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Richard H. Hunt, +7 more
- 01 Aug 2003 - 
TL;DR: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib is assessed by both endoscopy and analysis of upper gastrointestinal events.

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema

James Brian Byrd, +10 more
TL;DR: This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of angiotensin-converting enzyme inhibitor–associated angioedema, and found that it was true.